Jancy Nixon Abraham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jancy Nixon Abraham has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Devesh Rawat
Laboratory of Neural Circuits and Behaviour (LNCB), Department of Biology, Indian Institute of Science Education and Research (IISER), Pune, India
1 shared publicationLisni P. Sunny
Laboratory of Neural Circuits and Behaviour (LNCB), Department of Biology, Indian Institute of Science Education and Research (IISER), Pune, India
1 shared publication- Nixon M. Abraham
Department of Biology, Laboratory of Neural Circuits and Behaviour (LNCB) Indian Institute of Science Education and Research (IISER) Pune Maharashtra India
1 shared publication Priyadharshini Srikanth
Laboratory of Neural Circuits and Behaviour (LNCB), Department of Biology, Indian Institute of Science Education and Research (IISER), Pune, India
1 shared publication
Latest Publications
- Open Access
- 28 April 2025
- Published by Springer Nature in Mammalian Genome
- Vol. 36 (2) , 444-464
Alpha-synuclein pathology and Parkinson’s disease-related olfactory dysfunctions: an update on preclinical models and therapeutic approaches
Olfactory dysfunction (OD) is considered one of the early signs of Parkinson’s disease (PD), affecting over 90% of PD patients. OD often appears several years before the onset of motor symptoms and is therefore considered an early biomarker of PD. Recent studies have shown that COVID-19 infection might lead to worsening of symptoms and acceleration of disease progression in neurodegenerative disorders, where OD is a common symptom to both. Hence, it is essential to accurately monitor olfactory fitness in clinical settings using any of the currently available olfactory function tests. Even after a quarter of a century of the discovery of α-synuclein (α-syn) pathogenesis in PD, many aspects related to the α-syn pathogenesis in OD remain unknown. Currently, there is no definitive cure for PD; the disease management options include dopaminergic medications, deep brain stimulations, stem cells, and immunotherapy. Generating reliable PD animal models is critical for understanding the molecular pathways and neural circuits affected by disease conditions. This might contribute to the development and validation of new therapeutic approaches. This review discusses the known mechanisms of α-syn aggregated forms causing neuronal death, the recent developments in the PD preclinical models with ODs, and the treatment strategies employed.
- 28 April 2025
- Published by Springer Nature in Mammalian Genome
- Vol. 36 (2) , 444-464
Open AccessAlpha-synuclein pathology and Parkinson’s disease-related olfactory dysfunctions: an update on preclinical models and therapeutic approaches
Olfactory dysfunction (OD) is considered one of the early signs of Parkinson’s disease (PD), affecting over 90% of PD patients. OD often appears several years before the onset of motor symptoms and is therefore considered an early biomarker of PD. Recent studies have shown that COVID-19 infection might lead to worsening of symptoms and acceleration of disease progression in neurodegenerative disorders, where OD is a common symptom to both. Hence, it is essential to accurately monitor olfactory fitness in clinical settings using any of the currently available olfactory function tests. Even after a quarter of a century of the discovery of α-synuclein (α-syn) pathogenesis in PD, many aspects related to the α-syn pathogenesis in OD remain unknown. Currently, there is no definitive cure for PD; the disease management options include dopaminergic medications, deep brain stimulations, stem cells, and immunotherapy. Generating reliable PD animal models is critical for understanding the molecular pathways and neural circuits affected by disease conditions. This might contribute to the development and validation of new therapeutic approaches. This review discusses the known mechanisms of α-syn aggregated forms causing neuronal death, the recent developments in the PD preclinical models with ODs, and the treatment strategies employed.